is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
volves loss of epithelial polarity and E-cadherein, disruption of tubular basement membrane, acquisition of spindle-like morphology, de novo synthesis of ␣-smooth muscle actin (␣-SMA), and production of matrix proteins (22) .
Hepatocyte growth factor (HGF) has multiple biological activities in a wide variety of cell types. In carcinoma cells, HGF induces EMT, producing the invasive and metastatic phenotype (3, 11, 37) . In contrast, HGF inhibits EMT in renal epithelial cells, exhibiting beneficial effects on chronic renal disease (22) . In cultured renal proximal tubular cells, HGF blocks TGF-␤ 1 -induced EMT (43) . In several animal models of chronic renal disease, including rats with chronic allograft nephropathy (1) and mice with the ICR-derived glomerulonephritis (ICGN) (25) , administration with the recombinant HGF exhibits remarkable beneficial effects on the kidney. On the contrary, neutralization of endogenous HGF with anti-HGF antibody aggravates renal injury induced by ICGN (26) and obstructive nephropathy (27) . Administration of HGF clearly holds a promise for treatment of patients with ESRD. However, the molecular mechanism underlying the antifibrotic effects of HGF is still not fully characterized.
Prostaglandins (PGs) are a group of compounds derived from arachidonic acid through the cyclooxygenase (COX) pathway by constitutive COX-1-inducible COX-2 (38) . PGs play an important role in regulation of a wide spectrum of cellular functions in various cell types. A large body of experimental work documents that PGE 2 functions as an antifibrotic factor in the lung and reduction of PGE 2 levels contributes to the pathogenesis of pulmonary fibrosis (16, 23, 24) . In cultured lung fibroblasts, PGE 2 suppresses cell proliferation (13) , collagen production (14, 24) , and fibroblast-to-myofibroblast transition (20) . In contrast to the detailed knowledge about the antifibrotic function of PGE 2 in the lung, the role of PGE 2 in renal fibrosis is less understood. In addition, there is no information concerning the role of PGE 2 in regulation of EMT in renal tubular epithelial cells or other types of epithelial cells. The present study provides evidence that PGE 2 is a potent inhibitor of EMT in renal epithelial cells and COX-2-derived PGE 2 partially mediates the antifibrotic effect of HGF.
MATERIALS AND METHODS
Reagents and antibodies. Recombinant human HGF, TGF-␤1, epidermal growth factor (EGF), PDGF-BB, insulin-like growth factor (IGF)-1, and extracellular signal-regulated kinases 1/2 (ERK1/2) inhibitor, U-0126, were purchased from Calbiochem (Cambridge, MA).
8-Br-cAMP, forskolin, IBMX, Rp-cAMP, H89, antibodies against ␣-SMA, E-cadherin, and ␤-actin were purchased from Sigma (St. Louis, MO). Rabbit anti-murine COX-2 polyclonal antiserum was from Cayman (Ann Arbor, MI). Fluorescein isothiocyanate (FITC)-conjugated goat anti-rat IgG, horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit IgG were from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture. Madin-Darby canine kidney (MDCK) cells were cultured in DMEM, containing 10% FBS, 1% penicillin/streptomycin (GIBCO, Burlington, ON) at 37°C under 5% CO 2 in a humidified incubator. Cells were grown to 80% confluence, serum starved for 24 h, and then treated with vehicle or 50 ng/ml human recombinant HGF, TGF-␤ 1 with/without PGE2 for the indicated times. Microscopic examination was performed during each experiment to assess the morphological changes before sample analysis.
Western blotting. MDCK cells were lysed and subsequently sonicated in PBS containing 1% Triton X-100, 250 M PMSF, 2 mM EDTA, and 5 mM DTT (pH 7.5). Protein concentration was determined by Coomassie reagent. Thirty micrograms of protein from whole cell lysates were denatured in boiling water for 10 min, separated by SDS-PAGE, and transferred onto nitrocellulose membranes. The blots were blocked overnight with 5% nonfat dry milk in Tris-buffered saline (TBS), followed by incubation for 1 h with rabbit anti-murine polyclonal antiserum to COX-2 or mouse anti-␣-SMA monoclonal antibody. After being washed with TBS, blots were incubated with a goat anti-HRP-conjugated secondary antibody and visualized with ECL kits (Amersham). Immunoblotting of ␤-actin served as a loading control. Quantitative data were generated as arbitrary values relative to control and normalized by ␤-actin.
Immunofluorescence microscopy for E-cadherin. Cells were grown on coverslips and stimulated for 72 h with TGF-␤ 1 in the presence or absence of HGF or PGE2. The medium was removed, and the cell layer was rinsed with PBS. Cells were fixed and permeabilized with acetone-methanol for 10 min at Ϫ20°C and then were rehydrated with PBS and blocked with 5% BSA in PBS for 1 h. Coverslips were sequentially incubated with rat monoclonal anti-E-cadherin and FITC- Bottom: representative immunoblots. Quantitative data were generated as arbitrary values relative to control and normalized by ␤-actin. Unless otherwise specified, relative COX-2 and ␣-smooth muscle actin (SMA) protein levels shown in rest of the figures were all normalized by ␤-actin. B: time course of PGE2 stimulation. *P Ͻ 0.01. **P Ͻ 0.05 vs. controls. Fig. 2 . Effects of various growth factors on COX-2 expression and PGE2 production. MDCK cells were treated by EGF (20 ng/ml), IGF-1 (10 ng/ml), TGF-␤1 (10 ng/ml), and PDGF-BB (10 ng/ml) for 6 or 12 h, and COX-2 expression and PGE2 concentration were determined as described above. A: densitometric analysis of COX-2 protein expression. B: PGE2 concentration. Values are the mean intensity Ϯ SE of 3 independent experiments. labeled goat anti-rat antibody each for 60 min at room temperature. Cells were then visualized and photographed by fluorescence microscopy at ϫ40 magnification. Negative controls were performed using nonimmune serum or IgG instead of first antibodies.
PGE2 enzyme immunoassay. PGE2 in the culture media was measured with an enzyme immunoassay kit. The assay was performed according to the manufacturer's instruction. Briefly, 25 or 50 l of the medium, along with a serial dilution of PGE2 standard samples, were mixed with appropriate amounts of acetylcholinesterase-labeled tracer and PGE 2 antiserum and incubated at room temperature for 18 h. After the wells were emptied and rinsed with wash buffer, 200 l of Ellman's reagent were added.
Phosphorylation of MAP kinases. MDCK cells grown in a six-well plate were lysed by sonication for 10 s in 300 l of 1ϫ Laemmli sample buffer containing 10 mM Tris, 1.4% SDS, and 40 mM DTT (pH 6.8). The protein samples were heated at 60°C for 15 min and electrophoresis was performed. The blots were blocked in 5% nonfat dry milk for 1 h and incubated overnight at 4°C with the primary antibodies against phospho-ERK1/2 and phospho-p38 at a dilution of 1:1,000. The secondary antibody and ECL reaction were the same as described above.
DCFDA fluorescence measurement of reactive oxygen species. The fluorogenic substrate 2Ј,7Ј-dichlorofluorescein diacetate (DCFDA) is a cell-permeable dye that is oxidized to highly fluorescent 2Ј,7Ј-dichlorofluorescein (DCF) by H2O2 and can therefore be used to monitor intracellular generation of reactive oxygen species (ROS). For measurement of ROS, cells were grown onto glass cover slides. When the cells reached confluence, they were washed twice with PBS and incubated for 30 min with 50 M DCFDA diluted in Opti-MEM with 10% FCS. Then hypertonic medium was added. At the end of the incubation period, the cells were again washed twice with PBS and imaged by confocal laser microscopy. To quantitate ROS levels, cells were seeded to 96-well plates and were treated as described above. Relative fluorescence was measured using a fluorescence plate reader (FLUOstar OPTIMA) at excitation and emission wavelengths of 485 and 528 nm, respectively, three times at 90-s intervals.
cAMP assay. Serum-starved MDCK cells grown in six-well plates were pretreated with a phosphodiesterase inhibitor [3-isobutyl-1-methylxanthine (IBMX)] at 10 M for 30 min and then treated with 1 M PGE2. After treatment, medium was removed and the cells were washed with phosphate-buffered saline (PBS). Immediately after being washed, 0.5 ml of 0.1 M HCl was added. After 20 min, cells were scraped into a centrifuge tube and spun for 10 min at 1,000 g to pellet the cell debris. The cAMP enzyme-linked immunosorbent assay was performed according to manufacturer's instructions (Cayman Chemicals).
Statistical analysis. Values shown represent means Ϯ SE. Statistical analysis was performed by ANOVA and Bonferroni tests or independent sample t-test with a P value of Ͻ0.05 being considered statistically significant. 2 production. Treatment with HGF at 50 ng/ml elevated COX-2 protein expression by 230 Ϯ 13% (P Ͻ 0.01) at 3 h, and by 283 Ϯ 23% (P Ͻ 0.01) at 6 h, and the expression returned to basal levels at 12 h (Fig. 1A) . The induction of COX-2 expression was paralleled by a significant stimulation of PGE 2 release as determined by EIA. The stimulation of PGE 2 release following HGF treatment was detected at 3 h, gradually increasing with time with an maximal effect at 12 h (Fig. 1B) .
RESULTS

HGF specifically induced COX-2 expression and PGE
We performed parallel experiments to examine effects of other growth factors, including EGF, IGF-1, TGF-␤ 1 , and PDGF-BB, on the COX-2 expression as well as PGE 2 production. In contrast to HGF, none of the other growth factors tested had any significant effects on COX-2 expression or PGE 2 production (Fig. 2) .
Induction of COX-2 expression by HGF was mediated by ERK1/2. MAP kinase has emerged as a common downstream mediator in the stimulation of COX-2 expression in response to divergent stimuli. We examined involvement of ERK1/2 in HGF-induced COX-2 expression in MDCK cells. HGF at 50 ng/ml rapidly activated ERK1/2 as assessed by immunoblotting detection of phospho-ERK1/2 (Fig. 3A) . Pretreatment with an ERK1/2 inhibitor, U-0126 (10 M), completely blocked the COX-2 stimulation induced by HGF. U-0126 even reduced the basal levels of COX-2 expression (Fig. 3B) . No obvious cytotoxicities were observed with the dose and duration of the U-0126 treatment. (Fig. 4A) , whereas TGF-␤ 1 treatment for 3 days induced a complete conversion to spindle-like morphology (Fig. 4B) . The TGF-␤ 1 -induced morphologic changes were completely prevented by treatment with 1 M PGE 2 (Fig. 4C) .
E-cadherin, a classic epithelial cell marker, is a membranebound protein involved in cell-cell interactions in intact renal tubular epithelial cells. We then performed immunocytochemical analyses to monitor changes in E-cadherin protein expression. As expected, E-cadherin was expressed exclusively in the basolateral membrane of MDCK cells in basal state (Fig. 5A) . In contrast, incubation with 10 ng/ml TGF-␤ 1 for 3 days dramatically reduced E-cadherin expression (Fig. 5B) . The reduction of E-cadherin was completely prevented in the presence of 1 M PGE 2 (Fig. 5C ).
␣-SMA is an actin isoform specific to myofibroblasts and its expression undergoes characteristic changes during EMT. We monitored the changes in ␣-SMA expression using immunoblotting. ␣-SMA in MDCK cells was detected at a low level in basal state and was remarkably induced (3.6-fold) following a 3-day treatment with TGF-␤ 1 . PGE 2 in the dose range of 10 -1,000 nM inhibited TGF-␤ 1 -induced ␣-SMA expression in a dose-dependent manner. The ␣-SMA induction was significantly inhibited by 100 nM PGE 2 and was completely abolished by 1,000 nM PGE 2 (Fig. 6) .
Effects of SC-58635 on HGF-induced inhibition of EMT.
Given the observations that HGF stimulated COX-2 expression and PGE 2 release, and exogenous PGE 2 blocked EMT induced by TGF-␤ 1 , we speculate that COX-2 may mediate the action of HGF in MDCK cells. Thus we examined whether a COX-2-selective inhibitor, SC-58635, would prevent the antifibrotic effect of HGF. We found that exposure of MDCK cells to 50 ng/ml recombinant human HGF for 3 days reversed TGF-␤ 1 -induced EMT as evidenced by restoration of epithelial phenotype (Fig. 4D ) and E-cadherin expression (Fig. 5D ) and inhibition of ␣-SMA expression (Fig. 7) . However, in the presence of a COX-2-specific inhibitor, SC-58635, HGF-induced inhibition of EMT was partially but significantly blocked (Fig. 4E for morphology, Fig. 5E for E-cadherin immunostaining, and Fig. 7 for ␣-SMA expression). Mechanisms of the inhibitory effect of PGE 2 on EMT. ROS have been shown to mediate TGF-␤ 1 -induced EMT, thus we tested whether PGE 2 inhibited TGF-␤ 1 -induced ROS production. Cellular ROS increased threefold 30 min following TGF-␤ 1 treatment. This increase in ROS levels was completely blocked by 1 M PGE 2 (Fig. 8) .
cAMP processes antioxidant properties and is a major signaling mediator of PGE 2 . We hypothesize that PGE 2 may inhibit TGF-␤ 1 -induced ROS production via cAMP. As shown in Fig. 9 , PGE 2 significantly increased intracellular cAMP levels. To examine whether increases of cAMP levels will inhibit ROS generation, we examined effects of a cell membrane-permeable cAMP analog, 8-Br-cAMP (50 M), an adenylate cyclase activator, forskolin (50 M), and a phosphodiesterases inhibitor, IBMX (10 M), on TGF-␤ 1 -induced oxidant production. As shown in Fig. 10 , all three cAMPelevating agents were able to block the rise of ROS in response to TGF-␤ 1 .
We next tested whether PGE 2 blocked EMT via cAMP. MDCK cells were pretreated by Rp-cAMP, an cAMP analog, or H89, a protein kinase A (PKA) inhitibor, for 30 min, then incubated with TGF-␤ 1 and PGE 2 . Unexpectedly, neither RpcAMP nor H89 blocked the effect of PGE 2 (Fig. 11) .
DISCUSSION
EMT has emerged as a critical event in the pathogenesis of TIF. Knowledge concerning the regulatory mechanism of EMT may lead to the development of effective therapies to halt the progression of ESRD. The identification of a limited number of negative regulators of EMT, namely HGF and bone morphogenic protein 7 (47), has already shed light on the therapeutic interventions of the disease process. The present study contributes to the identification of a novel class of EMT inhibitors that are a lipid mediator, PGE 2 .
MDCK cells are one of the best-characterized renal epithelial cells and have been used by a number of studies to investigate various aspects of EMT (6, 15, 34) . Exposure of MDCK cells to TGF-␤ 1 for 3 days induced a complete conversion of the epithelial cells to myofibroblasts as evidenced by acquisition of spindle-like morphology, loss of E-cadherin, and activation of ␣-SMA. The time frame required for this transition was similar to previous reports (44) . PGE 2 exhibited a remarkable inhibitory effect on TGF-␤ 1 -induced EMT. This inhibition was complete as evidenced by a full restoration of epithelial morphology and E-cadherin expression and a complete abolishment of ␣-SMA stimulation. These effects were observed with PGE 2 at the range of 10 to 1,000 nM which is likely to be within the range of physiological concentrations of Fig. 9 . Effect of PGE2 on cAMP production. MDCK cells were grown to confluence and serum-starved for 24 h and then pretreated with 10 M IBMX for 30 min, followed by incubation with serum-free media alone or 1 M PGE2. Cells were harvested in 0.1 M HCl and supernatants were assayed for cAMP levels by ELISA. Values represent means Ϯ SE, n ϭ 6. *P Ͻ 0.01 vs. control. PGE 2 in the kidney. These observations strongly suggest that PGE 2 is a potent inhibitor of TGF-␤ 1 -induced EMT.
What would be the signaling mechanism responsible for PGE 2 -elicited inhibitory effects on EMT? ROS have an established role in the pathogenesis of chronic renal disease. Two recent studies have made a landmark observation that ROS mediates EMT in both cancer cells and renal proximal tubule cells (33, 36) . Therefore, we examined the possibility that PGE 2 may inhibit EMT via reduction of ROS production. We found that TGF-␤ 1 at 10 ng/ml induced a threefold increase in DCF-sensitive cellular ROS, confirming the report by Rhyu et al. (36) . To our surprise, 1 M PGE 2 completely blocked TGF-␤ 1 -induced ROS production, thus establishing ROS as a target of PGE 2 during EMT.
cAMP processes antioxidant properties and is a major signaling mediator of PGE 2 . We examined the potential role of cAMP as a proximal mediator of the signaling cascade elicited by PGE 2 . Indeed, all cAMP-elevating agents tested (8-BrcAMP, forskolin, and IBMX) mimicked the effect of PGE 2 in inhibiting oxidative stress and EMT. Furthermore, PGE 2 treatment was able to elevate intracellular cAMP level. These findings favor the notion that PGE 2 may act via cAMP. However, inhibition of the activity of endogenous cAMP with either Rp-cAMP or H89 failed to block the effect of PGE 2 , almost ruling out involvement of cAMP. One explanation is that the production of endogenous cAMP induced by PGE 2 may not reach the level achieved with cAMP-elevating agents for effective inhibition of EMT. It is possible that cAMP pathway may be utilized by other antifibrotic factors with more effective cAMP-elevating capability.
HGF is a novel antifibrotic cytokine that blocks TGF-␤ 1 -induced EMT both in vitro and in vivo. We sought to examine the possibility that the antifibrotic effect of HGF might be mediated by COX-2-derived PGE 2 . In the present study, we demonstrated that HGF transiently and significantly induced COX-2 expression that was paralleled by significant stimulation of PGE 2 release. In sharp contrast, exposure of MDCK cells to several other growth factors including EGF, TGF-␤ 1 , IGF-1, and PDGF-BB, had no effect on either COX-2 expression or PGE 2 release. These findings demonstrate that the induction of COX-2 in MDCK cells is specific to HGF but not other growth factors tested. In complete agreement with this finding, the inhibition of TGF-␤ 1 -induced EMT in cultured tubular epithelial HK cells is observed only with HGF, but not EGF, PDGF, IGF-1, and IL-6 (44). These findings indicate a specific coupling of the COX-2-PGE 2 pathway with HGF in MDCK cells. We further demonstrated that in the presence of a COX-2-specific inhibitor, SC-58635, the antifibrotic effect of HGF was blocked significantly although not completely, indicating some dependence of HGF action on COX-2 products.
COX-2 is an inducible form of cyclooxygenase and has been characterized as an immediate early responsive gene that can be induced by a wide variety of growth factors, tumor promoters, and cytokines, mostly in cancer cells and inflammatory cells (7, 12, 38) . In contrast, COX-2 expression in MDCK cells is induced by HGF but not other growth factors examined. In line with this observation, interleukin-1␤, TNF-␣, and phorbol 12-myristate 13-acetate (PMA) do not have any effect on COX-2 expression in MDCK cells (31) . The response of COX-2 to a selective growth factor HGF in MDCK cells suggests distinct functions. As demonstrated by the present study, this phenomenon is linked to the antifibrotic function of HGF, which is not shared with other growth factors.
The signaling pathway involved in the HGF induction of COX-2 expression was examined with emphasis on MAP kinase. Exposure of MDCK cells to HGF induced a rapid increase in phosphorylation of ERK1/2 that preceded the COX-2 induction. An ERK1/2 inhibitor, U-0126 (10 M), completely blocked the COX-2 stimulation. It is evident that ERK1/2 is required for the induction of COX-2 by HGF in cultured MDCK cells. In line with this observation, MAP kinases including ERK1/2 mediate COX-2 induction in renal epithelial cells following exposure to diverse stimuli, such as hypertonicity (45) and low chloride (46) . Taken together, these observations consolidate the conclusion that MAP kinases serve as a common downstream mediator for the stimulation of COX-2 expression. However, given the quite universal phenomenon of activation of ERK1/2 by different growth factors, the specificity of signaling pathway involved in HGF activation of COX-2 is considered to be conferred by other mediators in the pathway.
Given the ability of PGE 2 to inhibit TGF-␤ 1 -induced EMT, it is reasonable to speculate that PGE 2 will exhibit beneficial effects on renal injury associated with chronic renal disease. In a general agreement with this notion, a large number of early studies demonstrate that PGE or prostacyclin exerts beneficial actions to limit ischemic or toxic renal injury (19, 21, 29, 30, 40, 42) . The beneficial actions may relate to the improved renal perfusion (29) . It has also been shown that in cultured renal tubular epithelial cells PGE 2 and its analog 11-deoxy-16,16-dimethyl PGE 2 exert a direct cytoprotective action (17, 41) . On the other hand, inhibition of PG synthesis with nonsteroid anti-inflammatory drugs is associated with various types of nephrotoxicities, including interstitial nephritis (2, 44) . Furthermore, COX-2-deficient mice develop severe renal pathologies and progressive renal failure (8, 28) .
In summary, the present study documents a counterregulatory role of the COX-2-derived PGE 2 in EMT through inhibition of ROS production (Fig. 12) . This pathway partially mediates the antifibrotic action of HGF. These observations are expected to shed new light on a better understanding of the lipid mediators in chronic renal disease.
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